Does the media prefer TNYA or VSTM?

In the previous week, Tenaya Therapeutics and Tenaya Therapeutics both had 4 articles in the media. Tenaya Therapeutics' average media sentiment score of 1.14 beat Verastem's score of 0.81 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TNYA or AVTE more profitable?

Tenaya Therapeutics' return on equity of -83.75% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -83.75% -66.53% Aerovate Therapeutics N/A -90.19% -77.47%

Is TNYA or EIKN more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -83.75% -66.53% Eikon Therapeutics N/A N/A N/A

Does the media refer more to TNYA or EIKN?

In the previous week, Tenaya Therapeutics and Tenaya Therapeutics both had 4 articles in the media. Tenaya Therapeutics' average media sentiment score of 1.14 beat Eikon Therapeutics' score of 0.91 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TNYA or PRME?

In the previous week, Prime Medicine had 4 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 8 mentions for Prime Medicine and 4 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 1.14 beat Prime Medicine's score of 0.82 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TNYA or ALT?

In the previous week, Altimmune had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 7 mentions for Altimmune and 4 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 1.14 beat Altimmune's score of 0.75 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tenaya Therapeutics (TNYA) Competitors

$0.68 -0.01 (-1.30%)

As of 01:39 PM Eastern

Compare

TNYA vs. VSTM, AVTE, EIKN, PRME, and ALT

Should you buy Tenaya Therapeutics stock or one of its competitors? Tenaya Therapeutics's main competitors and comparable companies include Verastem (VSTM), Aerovate Therapeutics (AVTE), Eikon Therapeutics (EIKN), Prime Medicine (PRME), and Altimmune (ALT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tenaya Therapeutics compare to Verastem?

Tenaya Therapeutics (NASDAQ:TNYA) and Verastem (NASDAQ:VSTM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by insiders. Comparatively, 1.9% of Verastem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tenaya Therapeutics has higher earnings, but lower revenue than Verastem. Verastem is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	$1.34M	114.40	-$90.60M	-$0.53	N/A
Verastem	$87.53M	7.36	-$209.47M	-$2.66	N/A

Tenaya Therapeutics has a beta of 2.83, indicating that its stock price is 183% more volatile than the broader market. Comparatively, Verastem has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Tenaya Therapeutics has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Tenaya Therapeutics' return on equity of -83.75% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Verastem	-231.59%	-467.49%	-94.54%

Tenaya Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 487.29%. Verastem has a consensus price target of $13.83, suggesting a potential upside of 94.56%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Tenaya Therapeutics is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Tenaya Therapeutics and Tenaya Therapeutics both had 4 articles in the media. Tenaya Therapeutics' average media sentiment score of 1.14 beat Verastem's score of 0.81 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tenaya Therapeutics beats Verastem on 13 of the 15 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Aerovate Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

In the previous week, Tenaya Therapeutics had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 4 mentions for Tenaya Therapeutics and 0 mentions for Aerovate Therapeutics. Tenaya Therapeutics' average media sentiment score of 1.14 beat Aerovate Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tenaya Therapeutics	Positive
Aerovate Therapeutics	Neutral

Tenaya Therapeutics has a beta of 2.83, suggesting that its stock price is 183% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Tenaya Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 487.29%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Tenaya Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aerovate Therapeutics has lower revenue, but higher earnings than Tenaya Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	$1.34M	114.40	-$90.60M	-$0.53	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

90.5% of Tenaya Therapeutics shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tenaya Therapeutics' return on equity of -83.75% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Summary

Tenaya Therapeutics beats Aerovate Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Eikon Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Tenaya Therapeutics has higher revenue and earnings than Eikon Therapeutics. Eikon Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	$1.34M	114.40	-$90.60M	-$0.53	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

Tenaya Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 487.29%. Eikon Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 137.64%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Tenaya Therapeutics is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Eikon Therapeutics' return on equity of 0.00% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Eikon Therapeutics	N/A	N/A	N/A

In the previous week, Tenaya Therapeutics and Tenaya Therapeutics both had 4 articles in the media. Tenaya Therapeutics' average media sentiment score of 1.14 beat Eikon Therapeutics' score of 0.91 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.5% of Tenaya Therapeutics shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Tenaya Therapeutics beats Eikon Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Prime Medicine?

Tenaya Therapeutics (NASDAQ:TNYA) and Prime Medicine (NASDAQ:PRME) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Tenaya Therapeutics has higher earnings, but lower revenue than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	$1.34M	114.40	-$90.60M	-$0.53	N/A
Prime Medicine	$4.07M	158.53	-$201.14M	-$1.06	N/A

Tenaya Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 487.29%. Prime Medicine has a consensus price target of $7.47, suggesting a potential upside of 109.89%. Given Tenaya Therapeutics' higher probable upside, equities analysts plainly believe Tenaya Therapeutics is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Prime Medicine had 4 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 8 mentions for Prime Medicine and 4 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 1.14 beat Prime Medicine's score of 0.82 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Prime Medicine	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenaya Therapeutics has a beta of 2.83, indicating that its stock price is 183% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market.

Tenaya Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. Tenaya Therapeutics' return on equity of -83.75% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by insiders. Comparatively, 16.0% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Tenaya Therapeutics beats Prime Medicine on 9 of the 16 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Altimmune?

Tenaya Therapeutics (NASDAQ:TNYA) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Tenaya Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Altimmune	-214,860.98%	-31.41%	-26.96%

Tenaya Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 487.29%. Altimmune has a consensus target price of $14.33, suggesting a potential upside of 365.37%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by insiders. Comparatively, 1.6% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Altimmune has lower revenue, but higher earnings than Tenaya Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	$1.34M	114.40	-$90.60M	-$0.53	N/A
Altimmune	$40K	14,978.04	-$88.09M	-$0.78	N/A

In the previous week, Altimmune had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 7 mentions for Altimmune and 4 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 1.14 beat Altimmune's score of 0.75 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenaya Therapeutics has a beta of 2.83, suggesting that its stock price is 183% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Summary

Tenaya Therapeutics beats Altimmune on 11 of the 17 factors compared between the two stocks.

Get Tenaya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNYA vs. The Competition

Export

Metric	Tenaya Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$152.72M	$3.92B	$7.13B	$12.81B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-1.29	11.77	272.85	25.45
Price / Sales	114.40	1,393.83	685.78	122.48
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	1.19	16.75	11.02	6.33
Net Income	-$90.60M	-$22.71M	$3.47B	$349.46M
7 Day Performance	0.95%	2.15%	0.94%	-0.29%
1 Month Performance	-8.00%	12.31%	7.93%	4.18%
1 Year Performance	-39.73%	53.90%	23.74%	14.53%

Tenaya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNYA Tenaya Therapeutics	2.8266 of 5 stars	$0.68 -1.3%	$4.00 +487.3%	-38.9%	$152.72M	$1.34M	N/A	110	Positive News Analyst Downgrade
VSTM Verastem	3.17 of 5 stars	$6.86 -0.4%	$13.83 +101.7%	-21.9%	$623.98M	$30.91M	N/A	50
AVTE Aerovate Therapeutics	N/A	$21.34 +0.5%	N/A	+163.8%	$618.54M	N/A	N/A	20	High Trading Volume
EIKN Eikon Therapeutics	3.494 of 5 stars	$11.16 -2.0%	$25.00 +124.0%	N/A	$616.94M	N/A	N/A	384
PRME Prime Medicine	2.7569 of 5 stars	$3.25 -4.1%	$7.69 +136.8%	N/A	$614.87M	$4.63M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNYA) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. VSTM, AVTE, EIKN, PRME, and ALT

How does Tenaya Therapeutics compare to Verastem?

Summary

How does Tenaya Therapeutics compare to Aerovate Therapeutics?

Summary

How does Tenaya Therapeutics compare to Eikon Therapeutics?

Summary

How does Tenaya Therapeutics compare to Prime Medicine?

Summary

How does Tenaya Therapeutics compare to Altimmune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. VSTM, AVTE, EIKN, PRME, and ALT

How does Tenaya Therapeutics compare to Verastem?

Do insiders & institutionals believe in TNYA or VSTM?

Which has preferable earnings & valuation, TNYA or VSTM?

Which has more volatility and risk, TNYA or VSTM?

Is TNYA or VSTM more profitable?

Do analysts prefer TNYA or VSTM?

Does the media prefer TNYA or VSTM?

Summary

How does Tenaya Therapeutics compare to Aerovate Therapeutics?

Does the media refer more to TNYA or AVTE?

Which has more risk & volatility, TNYA or AVTE?

Do analysts recommend TNYA or AVTE?

Which has stronger earnings & valuation, TNYA or AVTE?

Do institutionals & insiders hold more shares of TNYA or AVTE?

Is TNYA or AVTE more profitable?

Summary

How does Tenaya Therapeutics compare to Eikon Therapeutics?

Which has higher valuation and earnings, TNYA or EIKN?

Do analysts rate TNYA or EIKN?

Is TNYA or EIKN more profitable?

Does the media refer more to TNYA or EIKN?

Do insiders and institutionals hold more shares of TNYA or EIKN?

Summary

How does Tenaya Therapeutics compare to Prime Medicine?

Which has higher earnings and valuation, TNYA or PRME?

Do analysts rate TNYA or PRME?

Does the media favor TNYA or PRME?

Which has more risk & volatility, TNYA or PRME?

Is TNYA or PRME more profitable?

Do institutionals and insiders believe in TNYA or PRME?

Summary

How does Tenaya Therapeutics compare to Altimmune?

Is TNYA or ALT more profitable?

Do analysts prefer TNYA or ALT?

Do institutionals and insiders believe in TNYA or ALT?

Which has preferable valuation & earnings, TNYA or ALT?

Does the media refer more to TNYA or ALT?

Which has more volatility & risk, TNYA or ALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools